WAYNE and UTRECHT – Feb. 4, 2025 — NanoCell Therapeutics, Inc. (“NanoCell”), a company developing a non-viral, DNA-based in vivo gene therapy platform, today announced that its CEO, Dr. Maurits Geerlings, will attend two upcoming investor conferences: BIO CEO & Investor Conference in New York City (Feb 10-11, 2025) and BIO-Europe Spring in Milan (March 17-19, 2025).
During these events, Dr. Geerlings will provide insights into NanoCell’s latest progress, including advancements in NCTX-1, its dual-CAR CD19/CD22 in vivo CAR-T therapy for B cell malignancies, as well as opportunities for strategic partnerships and investment. One-on-one meetings will be held to discuss NanoCell’s pioneering approach to in-vivo CAR-T cell generation using targeted lipid nanoparticles (tLNPs) and the company’s broader vision for revolutionizing adoptive cell therapy.
Conference Details:
BIO CEO & Investor Conference
Date: February 10–11, 2025
Location: New York, NY
Format: 1×1 Meetings
BIO-Europe Spring
Date: March 17–19, 2025
Location: Milan, Italy
Format: 1×1 Meetings
To learn more about our work and stay updated about our latest developments, please visit our website at http://www.nanocelltx.com.
About NanoCell Therapeutics, Inc.
NanoCell Therapeutics is a privately held, transatlantic biotechnology company with locations in Wayne, Pennsylvania, and Utrecht, the Netherlands. We are dedicated to pioneering transformative in-vivo cell engineering through our non-viral, DNA-based gene therapy platform, primarily targeting oncology and autoimmune diseases.